Randomized Double-Blind Trial in Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen.
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2017
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen
- Indications Breast cancer; Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IES; PathIES
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 24 Feb 2012 Planned patient number of the sub study (UKCRN 4208) is 2740.
- 24 Feb 2012 Planned end date of the sub study (UKCRN 4208) is 25 Feb 2003.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History